Shareholders approve increase in stock option plan shares by 900,000 at 2026 annual meeting

ProMIS Neurosciences Inc.

All 7 director nominees elected; broker non-votes of 614,643.
Ratification of Baker Tilly as auditor approved: 4,657,634 for, 4,415 against.
Amendment to 2025 Plan increases shares available to 1,017,868 from 117,868.
Shareholders representing 53.1% of outstanding common shares present at meeting.

item 5.02item 5.07item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.